Fox Chase Cancer Center
Who we are
Fox Chase Cancer Center is the only National Cancer Institute–designated Comprehensive Cancer Center in the Philadelphia region dedicated solely to cancer.
Fox Chase has a century-long history of important basic and clinical research, a distinction that includes two Nobel Prizes, a Lasker Award, a Kyoto Prize, a Szent Gyorgi Prize and many other high-level accolades. Fox Chase discovered the Philadelphia Chromosome in 1959, which led to the era of precision medicine in cancer. In 2022, Fox Chase became one of only two centers in the country to receive the National Cancer Institute’s Cancer Prevention-Interception Targeted Agent Discovery Program grant.
Fox Chase ranks as high performing in US News & World Report in its annual Best Hospital listing, and its physicians have a strong presence among Philadelphia Magazine’s Top Doctors. The center has achieved Magnet designation for nursing excellence six consecutive times, making the center among only 2 percent of hospitals nationwide to have achieved this distinction.
Fox Chase Cancer Center has received accreditation from the Joint Commission, the National Accreditation Program for Breast Cancers, the Foundation for the Accreditation of Cellular Therapy, the American College of Radiology, and the American College of Surgeons Commission on Cancer.
In 2023, Fox Chase received the prestigious Gold Certification for Excellence in Person-Centered Care from Planetree International. Fox Chase’s nationally recognized physicians offer a full range of top-quality cancer programs for all types of adult cancers, including rare and difficult-to-treat tumors. The philosophy of care focuses on providing multidisciplinary treatment in an environment dedicated to caring for the whole person. The Center also maintains strong programs in cancer risk and prevention, minimally invasive surgery, urology, hematology-oncology, and women’s cancers.
In 2012, Fox Chase became a member of the Temple University Health System. The health system has committed to making capital investments in both hospital infrastructure and research capacity to optimize cancer discovery and cancer care delivery.